Zura Bio Limited, a multi-asset clinical-stage biotechnology company focused on developing medicines for immune and inflammatory disorders, appointed Michael Howell chief scientific officer and head of translational science.

Howell brings more than two decades of experience leading discovery, translational research, and early clinical programs and will lead the scientific strategy and translational science efforts at Zura Bio.

“I am thrilled to have Michael Howell join our team as our Chief Scientific Officer and Head of Translational Science,” said Someit Sidhu, CEO of Zura Bio. “He brings over 20 years of significant experience in the pharmaceutical industry. He is an experienced industry leader with a proven track record of success, and I am confident that his expertise and vision will be key to advancing our science, partnerships, and clinical development pipeline. He will be a great addition to the executive management team of the company.”

Howell initially joined Zura Bio in 2022 as a scientific advisor during the company’s formation and acquisition of its first two clinical programs. He is a founding member of Galileo Biosystems Inc, a scientific advisor at Ornovi, Inc., and founder of Mountaineer Biosciences, Inc., and formerly served as the chief scientific officer of DermTech, Inc.

Previously, he held scientific leadership positions at Incyte Corporation, MedImmune, LLC /Astra Zeneca, the Immune Tolerance Network, and Boehringer Ingelheim GmbH.